News

  • 22 January 2008

    Novexel, the pharmaceutical company focused on the discovery and development of novel antibacterials and anti-fungals, today announces that it has entered into an agreement with Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. (NYSE: FRX), for the development, manufacture and commercialization of Novexel's novel intravenous beta lactamase inhibitor, NXL104 in combination with Forest’s ceftaroline. NXL104 is designed to be co- administered with select antibiotics to enhance their spectrum of activity. 

  • 4 December 2007

    PregLem, a Swiss specialty biopharmaceutical company focused on the development and commercialization of innovative therapeutic compounds for female reproductive medicine, today announced the closing of a CHF 36 million Series B financing round (€22.5 million). The lead investor is Sofinnova Ventures from San Francisco (CA) and returning investors include Sofinnova Partners (Seed Investor and Series A Lead Investor - Paris), MVM Life Science Partners LLP (London), and NeoMed Management (Geneva). The Series B will enable the development of a molecule licensed-in from privately- held French company, HRA Pharma, for the pre-operative treatment of uterine myoma. PregLem has successfully raised CHF 68 million in less than one year.

  • 8 November 2007

    Novexel, the specialty pharmaceutical company focused on the discovery and development of novel antibacterials and anti-fungals, today announces that it has raised €50 million in a Series B fundraising. The round was led by new investor, Edmond de Rothschild Investment Partners of Paris and included participation from all Novexel’s existing investors (Atlas Venture, Sofinnova, Abingworth, 3i, Novo A/S and BIT), as well as other new investors, Goldman Sachs, NeoMed and NIF SMBC (Tokyo). The funding is the largest raised by a private European company in this sector in the last twelve months.

  • 23 August 2007

    EUSA Pharma Inc (“EUSA"), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced the acquisition of the assets of Innocoll Inc ('Innocoll'). 

  • 27 June 2007

    PregLem today announced the closing of a CHF 32 million Series-A financing round (€20 million). The Series A financing round was led by Sofinnova Partners, and co-led by NeoMed Management and MVM Life Science Partners LLP. Concurrently, PregLem signed a licensing agreement with Ipsen (Euronext: IPN) under which Ipsen will grant PregLem worldwide development and commercialization rights to certain Ipsen compounds, for use in reproductive medicine only. The details of the agreement are not being disclosed. The funding will allow PregLem to undertake the development of these and other key compounds in the PregLem portfolio.